Different doses of UBT251 for adults with overweight or obesity

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a Phase 2, randomized, placebo-controlled interventional study testing safety and effectiveness of UBT251 in adults with excess weight. Participants are randomized to receive UBT251 or placebo at clinical sites in California, Kansas, and Quebec. The study is organized into Parts A, B, and C with different age and BMI entry ranges and Part C enrolling self‑reported Japanese, Chinese, or non‑Asian participants as specified. Safety, tolerability, and weight-related measures will be collected during the treatment period to compare outcomes between active drug and placebo.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Male or female (sex at birth).
2. For Part C: Japanese, Chinese or non-Asian participants (all self-reported):

   * For Japanese participants: both parents of Japanese descent.
   * For Chinese participants: both parents of Chinese descent.
   * For non-Asian participants: both parents of non-Asian descent (non-Asian is defined as of countries outside of Asia).
3. Age at the time of signing the informed consent:

   1. For Part A: 18-55 years (both inclusive)
   2. For Part B: 18-65 years (both inclusive)
   3. For Part C: 18-55 years (both inclusive).
4. BMI at screening (overweight and obesity should be due to excess adipose tissue, as judged by the investigator):

   1. For Part A: 27.0-39.9 kilogram per meter square (kg/m\^2) (both inclusive)
   2. For Part B: 30.0-50.0 kg/m\^2 (both inclusive)
   3. For Part C: 24-34.9 kg/m\^2 (both inclusive)
5. Considered eligible based on the medical history, physical examination, and the results of vital signs, electrocardiogram (ECG), and clinical laboratory tests performed during the screening visit, as judged by the investigator.

Exclusion Criteria:

1. Known or suspected hypersensitivity to study intervention(s) or related products.
2. Treatment with any marketed product containing compounds with glucagon-like peptide 1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP) or glucagon receptor agonism within 90 days before screening.
3. Any condition, unwillingness or inability, which in the investigator's opinion might jeopardise the participant's safety or compliance with the protocol.

Where it's running

• Altasciences Clinical LA, Inc.
  Cypress, California, United States Recruiting
• Altasciences Clinical Kansas, Inc.
  Overland Park, Kansas, United States Recruiting
• Altasciences Clinical Company, Inc
  Montreal, Quebec, Canada Recruiting

Study contacts

• Study coordinator: Novo Nordisk
• Email: clinicaltrials@novonordisk.com
• Phone: (+1) 866-867-7178

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Berobenatide for knee pain in adults who are overweight or with obesity

  This study tests berobenatide vs. placebo to see if it reduces knee pain and improves function while helping with weight in adults with knee osteoarthritis and overweight/obesity.

  Recruiting at 7 sites Phase 3 Pfizer · Tempe, Arizona and 39 other locations · NCT07919678

• Maridebart cafraglutide in people who switched from weekly GLP-1 receptor agonists

  This study tests how much maridebart cafraglutide appears in the blood after people with overweight or obesity switch from weekly GLP-1 receptor agonists.

  Recruiting at 9 sites Phase 1 Amgen · Phoenix, Arizona and 8 other locations · NCT07908316

• EloraTZP for weight loss in adults with overweight/obesity and type 2 diabetes

  This trial tests whether a coformulation of eloralintide and tirzepatide helps people with obesity or overweight and type 2 diabetes lose weight compared with tirzepatide alone.

  Recruiting Phase 3 Eli Lilly and Company · Tucson, Arizona and 74 other locations · NCT07881458

• Monthly dose of PF-08653944 vs placebo in Chinese adults who are overweight or obese

  This study tests whether berobenatide (PF-08653944) given once a month helps adults in China lose weight compared with a placebo.

  Recruiting Phase 3 Pfizer · Hefei, Anhui and 5 other locations · NCT07874633

• FutureShape Family: a family-based weight-management program with semaglutide for children and parents

  This trial tests whether a family-centered program that combines a prescription medication (semaglutide) with lifestyle support and app-based coaching can help adults with obesity and their children who are overweight/obese.

  Recruiting Phase 4 University of Copenhagen · Copenhagen · NCT07872904

• Home self-administration of a weight-management medicine with an autoinjector in adults who are overweight or obese

  This study tests whether adults who are overweight or have obesity can successfully self-administer maridebart cafraglutide at home using an autoinjector.

  Recruiting at 25 sites Phase 3 Amgen · San Diego, California and 24 other locations · NCT07871409

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.